U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Fallopian Tube Clear Cell Adenocarcinoma

MedGen UID:
1793969
•Concept ID:
C5557528
•
Neoplastic Process

Definition

Fallopian tube clear cell adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Fallopian Tube Clear Cell Adenocarcinoma

Recent clinical studies

Etiology

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P
Gynecol Oncol 2014 Jun;133(3):427-32. Epub 2014 Apr 5 doi: 10.1016/j.ygyno.2014.03.576. PMID: 24713545
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A
Asian Pac J Cancer Prev 2013;14(3):2131-5. doi: 10.7314/apjcp.2013.14.3.2131. PMID: 23679331

Therapy

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P
Gynecol Oncol 2014 Jun;133(3):427-32. Epub 2014 Apr 5 doi: 10.1016/j.ygyno.2014.03.576. PMID: 24713545
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A
Asian Pac J Cancer Prev 2013;14(3):2131-5. doi: 10.7314/apjcp.2013.14.3.2131. PMID: 23679331
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M
Am J Clin Oncol 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221. PMID: 18838885

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A
Asian Pac J Cancer Prev 2013;14(3):2131-5. doi: 10.7314/apjcp.2013.14.3.2131. PMID: 23679331
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M
Am J Clin Oncol 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221. PMID: 18838885

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M
Am J Clin Oncol 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221. PMID: 18838885

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...